Augmenix announces positive three-year long-term data highlighting benefits of SpaceOAR Hydrogel Spacer for patients with prostate cancer

Augmenix announced that the International Journal of Radiation Oncology Biology and Physics has published long-term outcomes data from the company’s Phase 3 clinical trial for SpaceOAR System, the first absorbable hydrogel spacer designed to separate the rectum and prostate during prostate cancer radiotherapy.
Business Wire